Arylpiperazine-containing pyrimidine 4-carboxamide derivatives targeting serotonin 5-HT2A, 5-HT2C, and the serotonin transporter as a potential antidepressant

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 22, 2010, Pages 6439-6442

  Kim, Jong Yup ^a,b   Kim, Deukjoon ^b   Kang, Suk Youn ^a   Park, Woo Kyu ^c   Kim, Hyun Jung ^a   Jung, Myung Eun ^a   Son, Eun Jung ^a   Pae, Ae Nim ^d   Kim, Jeongmin ^a   Lee, Jinhwa ^a  

^a Green Cross Company   (South Korea)

^b Seoul National University   (South Korea)

^c Korea Research Institute of Chemical Technology   (South Korea)

^d Korea Institute of Science and Technology   (South Korea)

Author keywords

Antidepressant; Piperazine; Pyrimidine; Serotonin

Indexed keywords

2 [[(7 FLUORO 4 INDANYL)OXY]METHYL]MORPHOLINE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; LY 367265; NEFAZODONE; POTASSIUM CHANNEL HERG; PYRIMIDINE DERIVATIVE; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; EVALUATION; FORCED SWIMMING TEST; IC 50; LOCOMOTION; NONHUMAN; STRUCTURE ACTIVITY RELATION;

AMIDES; ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; MICE; PIPERAZINES; PYRIMIDINES; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

ANIMALIA;

EID: 77958061381     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.09.081     Document Type: Article

References (21)

1. S. Quraishi, and S. Frangou J. Affect. Disord. 72 2002 209
2. A. Olley, G.S. Malhi, P.B. Mitchell, J. Batchelor, J. Lagopoulos, and M.-P.V. Austin J. Nerv. Ment. Dis. 193 2005 323
3. J.M. Keith, L.A. Gomez, R.L. Wolin, A.J. Barbier, S.J. Wilson, J.D. Boggs, C. Majur, I.C. Fraser, B. Lord, L. Aluisio, T.W. Lovenburg, and N.I. Carruthers Bioorg. Med. Chem. Lett. 17 2007 2603
4. I. Hindmarch Hum. Psychopharmacol. Clin. Exp. 16 2001 203
5. J.I. Andrés, J. Alcázar, J.M. Alonso, R.M. Alvarez, M.H. Bakker, I. Biesmans, J.M. Cid, A.I. De Lucas, W. Drinkenburg, J. Fernández, L.M. Font, L. Iturrino, X. Langlois, I. Lenaerts, S. Martínez, A.A. Megens, J. Pastor, S. Pullan, and T. Steckler Bioorg. Med. Chem. 15 2007 3649
6. S.Y. Kang, E.-J. Park, W.-K. Park, H.J. Kim, D. Jeong, M.E. Jung, K.S. Song, S.H. Lee, H.J. Seo, M.J. Kim, M. Lee, H.-K. Han, E.-J. Son, A.N. Pae, J. Kim, and J. Lee Bioorg. Med. Chem. Lett. 20 2010 1705
7. S.Y. Kang, E.-J. Park, W.-K. Park, H.J. Kim, G. Choi, M.E. Jung, H.J. Seo, M.J. Kim, A.N. Pae, J. Kim, and J. Lee Bioorg. Med. Chem. 18 2010 6156
8. K. Hatanaka, T. Nomura, K. Hidaka, H. Takeuchi, S. Yatsuki, M. Fujii, and T. Yamaguchi Neuropharmacology 35 1997 1621
9. I.A. Pullar, S.L. Carney, E.M. Colvin, V.L. Lucaites, D.L. Nelson, and S. Wedley Eur. J. Pharmacol. 407 2000 39
10. C. De Battista, M. Sofuogula, and A.F. Schatzberg Biol. Psychiatry 44 1998 341
11. D.S. Greene, and R.H. Barbhaiya Clin. Pharmacokinet. 33 1997 260
12. Y. Odagaki, R. Toyoshima, and T. Yamauchi J. Psychopharmacol. 19 2005 235
13. K.S. Ly, M.A. Letavic, J.M. Keith, J.M. Miller, E.M. Stocking, A.J. Barbier, P. Bonaventure, B. Lord, X. Jiang, J.D. Boggs, L. Dvorak, K.L. Miller, D. Nepomuceno, S.J. Wilson, and N.I. Carruthers Bioorg. Med. Chem. Lett. 18 2008 39
14. G. Bagdy, M. Graf, Z.E. Anheuer, E.A. Modos, and S. Kantor Int. J. Neuropharmacol. 4 2001 399
15. M.J. Robarge, S.M. Husbands, A. Kieltyka, R. Brodbeck, A. Thurkauf, and A.H. Newman J. Med. Chem. 44 2001 3175
16. W.-K. Park, D. Jeong, H. Cho, S.J. Lee, M.Y. Cha, A.N. Pae, K.I. Choi, H.Y. Koh, and J.Y. Kong Pharmacol. Biochem. Behav. 82 2005 361
17. 3H]Imipramine (PerkinElmer) and appropriate concentrations of test compounds were added to 0.25 mL assay buffer of 50 mM Tris-HCl (pH 7.4) containing 120 mM NaCl and 5 mM KCl. Incubations were carried out for 30 min at 27 °C, and these were terminated by rapid filtration through Filtermat A glass fiber filter presoaked in 0.5% PEI. Imipramine (100 μM) was used as the nonspecific ligand.
18. R.D. Porsolt, A. Bertin, and M. Jalfre Eur. J. Pharmacol. 51 1978 291
19. 17 Each mouse was placed in a 25-cm glass cylinder (10 cm diameter) containing 15 cm of water maintained at 23 ± 1 °C, and was forced to swim for 10 min. Later (24 h), the mouse was replaced 360 into the cylinder and the total duration of immobility was recorded during the last 5 min of the 6-min testing period. Mice are judged immobile when they float in an upright position and make only small movements to keep their head above water. Test compound (25 mg/kg) and sertraline (25 mg/kg) were suspended in 3%-Tween 80 solution, and administered (ip) 30 min before the testing.
20. + 400.
21. We have other supporting data involving in vivo efficacy tests in different animal model (e.g., tail suspension test) at the stage of lead selection. However, functional assay for selected compounds will be performed in the due course.